Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 48 systematic review(s)/meta-analysis(es). ^[1-48]
• Apalutamide significantly improved Overall Survival (OS) in high-volume metastatic hormone-sensitive prostate cancer (mHSPC) patients, with a hazard ratio (HR) of 0.70 (95% confidence interval (CI): 0.56-0.88), compared to androgen deprivation therapy (ADT) alone.
• No significant difference in Event-Free Survival (EFS) or OS was observed between intermittent PEG-asparaginase (eight doses) and continuous PEG-asparaginase (15 doses) in non-high risk acute lymphoblastic leukemia (ALL) patients. Similarly, there was no difference between low-risk standard treatment with additional PEG-asparaginase (six doses) and standard treatment (two doses), with risk ratios (RR) close to 1.
• Rifamycin-SV significantly reduced Time to Last Unformed Stool (TLUS) compared to placebo in all severity groups, with a HR of 1.
• Apalutamide was associated with a notable improvement in Progression-Free Survival (PFS) in high-volume mHSPC, with a HR of 0.73 (95% CI: 0.65-0.81), compared to androgen-deprivation therapy (ADT) alone.
• In non-metastatic castration-resistant prostate cancer (nmCRPC), apalutamide significantly increased Metastasis-Free Survival (MFS), with a hazard ratio (HR) of 0.28 (95% CI: 0.23-0.35), compared to placebo.
• Apalutamide had a higher incidence of Grade 3 or higher adverse events (AEs), with an odds ratio (OR) of 1.9 (95% CI: 1.4-2.7), compared to placebo, and a higher risk of serious adverse events (OR = 1.9, 95% CI: 1.3-2.8). There was also an increased risk of cognitive toxic effects (RR, 2.10; 95% CI: 1.30-3.38) and a higher risk of falls (RR = 1.87, 95% CI: 1.27-2.75).
• Apalutamide maintained health-related quality of life (HRQoL) similarly to ADT alone or in combination with docetaxel, with no significant prolongation of time to first deterioration of pain.
• There is no population types or subgroups information available in the reviewed studies.